Skip to content

Clinical Evaluation of Bixie Tongli Granules in Treating Type III Prostatitis with Dampness-Heat and Blood Stasis Pattern Based on the "Unblocking Method" Theory of Xin'an Medicine

Clinical Evaluation of Bixie Tongli Granules in Treating Type III Prostatitis with Dampness-Heat and Blood Stasis Pattern Based on the "Unblocking Method" Theory of Xin'an Medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000952
Enrollment
Unknown
Registered
2026-04-16
Start date
2024-03-16
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic prostatitis

Interventions

Western medicine control group:Oral Tamsulosin Hydrochloride Extended-Release Capsules
Bieju Tongli Granules Full Dose Group:The full dosage of the herbal formula Biege Jia Tongli Granules was administered in combination with the oral prescription drug Tamsulosin hydrochloride capsules.
Bie Xie Tong Li Chinese Herbal Formula Granules 2/3 Dosage Group:Take the oral prescription drug Tamsulosin hydrochloride capsules as the base and take 2/3 the dose of the traditional Chinese medicine
Bai Xie (Rhizoma Smilacis Glabrae) promoting diuresis Chinese herbal decoction pieces:In addition to orally administering the Western medicine Tamsulosin hydrochloride capsules, take the traditional C

Sponsors

Hu Qinglin
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for chronic type III prostatitis in Western medicine; 2. Identified in traditional Chinese medicine as a pattern of damp-heat descending and blood stasis obstruction; 3. Disease duration of at least 3 months; 4. Age over 18 years; 5. Patient voluntarily signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with concomitant diseases of the urological and andrological systems; 2. Patients with severe cardiovascular diseases or impaired liver or kidney function; 3. Patients with diagnosed mental disorders; 4. Patients with a known allergy to drugs involved in this study; 5. Patients who received drug therapy for chronic prostatitis or other related interventions within the two weeks prior to enrollment; 6. Patients who participated in other clinical trials within the past three months.

Design outcomes

Primary

MeasureTime frame
Clinical Efficacy Evaluation;TCM Syndrome Score;Chronic Prostatitis Symptom Score (NIH-CPSI);

Secondary

MeasureTime frame
Urine Prostate Secretory Small Body Protein;

Countries

China

Contacts

Public ContactHu Qinglin

Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine?

zxf9120@163.com18905501096

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026